Richard Rudick

Summary

Affiliation: Cleveland Clinic Foundation
Country: USA

Publications

  1. ncbi Reliability of classifying multiple sclerosis disease activity using magnetic resonance imaging in a multiple sclerosis clinic
    Edru Erbayat Altay
    Cleveland Clinic Mellen Center for Multiple Sclerosis Treatment and Research, 9500 Euclid Ave, Cleveland, OH 44195 5244, USA
    JAMA Neurol 70:338-44. 2013
  2. ncbi Natalizumab: bench to bedside and beyond
    Richard Rudick
    Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    JAMA Neurol 70:172-82. 2013
  3. ncbi LINGO-1 antagonists as therapy for multiple sclerosis: in vitro and in vivo evidence
    Richard A Rudick
    Mellen Center for Multiple Sclerosis Treatment and Research, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA
    Expert Opin Biol Ther 8:1561-70. 2008
  4. ncbi Health-related quality of life in multiple sclerosis: current evidence, measurement and effects of disease severity and treatment
    Richard A Rudick
    Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    CNS Drugs 22:827-39. 2008
  5. ncbi Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal study
    Richard A Rudick
    Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland, OH, USA
    Ann Neurol 60:236-42. 2006
  6. ncbi Natalizumab plus interferon beta-1a for relapsing multiple sclerosis
    Richard A Rudick
    Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    N Engl J Med 354:911-23. 2006
  7. ncbi Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients
    R A Rudick
    Department of Neurology, Mellen Center for Multiple Sclerosis Treatment and Research, The Cleveland Clinic Foundation, OH 44195, USA
    Mult Scler 11:626-34. 2005
  8. ncbi Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS
    Richard A Rudick
    Department of Neurology, Center for Multiple Sclerosis Treatment and Research, Cleveland, OH 44195, USA
    Expert Rev Neurother 4:571-80. 2004
  9. ncbi Impact of disease-modifying therapies on brain and spinal cord atrophy in multiple sclerosis
    Richard A Rudick
    Department of Neurology, Mellen Center for Multiple Sclerosis Treatment and Research, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    J Neuroimaging 14:54S-64S. 2004
  10. ncbi Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS
    Richard A Rudick
    Mellen Center for MS Treatment and Research U10, Neurologic Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Neurol Sci 282:106-11. 2009

Research Grants

  1. EXTRAMURAL RESEARCH FACILITIES IMPROVEMENT PROGRAM GCRC
    Richard Rudick; Fiscal Year: 2003
  2. GENERAL CLINICAL RESEARCH CENTER
    Richard Rudick; Fiscal Year: 2006
  3. Case/Cleveland Clinic Clinical Research Training Program (RMI)
    Richard Rudick; Fiscal Year: 2007

Detail Information

Publications70

  1. ncbi Reliability of classifying multiple sclerosis disease activity using magnetic resonance imaging in a multiple sclerosis clinic
    Edru Erbayat Altay
    Cleveland Clinic Mellen Center for Multiple Sclerosis Treatment and Research, 9500 Euclid Ave, Cleveland, OH 44195 5244, USA
    JAMA Neurol 70:338-44. 2013
    ..To assess the reliability of new magnetic resonance imaging (MRI) lesion counts by clinicians in a multiple sclerosis specialty clinic...
  2. ncbi Natalizumab: bench to bedside and beyond
    Richard Rudick
    Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    JAMA Neurol 70:172-82. 2013
    ..The natalizumab story highlights both the opportunities and risks inherent in a novel biological therapy for a progressive neurologic disease...
  3. ncbi LINGO-1 antagonists as therapy for multiple sclerosis: in vitro and in vivo evidence
    Richard A Rudick
    Mellen Center for Multiple Sclerosis Treatment and Research, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA
    Expert Opin Biol Ther 8:1561-70. 2008
    ..Leucine-rich repeats and Ig domain-containing, neurite outgrowth inhibitor (Nogo) receptor-interacting protein-1 (LINGO-1) is a potent negative regulator of axonal myelination...
  4. ncbi Health-related quality of life in multiple sclerosis: current evidence, measurement and effects of disease severity and treatment
    Richard A Rudick
    Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    CNS Drugs 22:827-39. 2008
    ....
  5. ncbi Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal study
    Richard A Rudick
    Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland, OH, USA
    Ann Neurol 60:236-42. 2006
    ..To evaluate the relation between T2 lesions and disease severity in relapsing-remitting multiple sclerosis (MS)...
  6. ncbi Natalizumab plus interferon beta-1a for relapsing multiple sclerosis
    Richard A Rudick
    Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    N Engl J Med 354:911-23. 2006
    ..Despite interferon beta therapy, many patients have relapses. Natalizumab, an alpha4 integrin antagonist, appeared to be safe and effective alone and when added to interferon beta-1a in preliminary studies...
  7. ncbi Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients
    R A Rudick
    Department of Neurology, Mellen Center for Multiple Sclerosis Treatment and Research, The Cleveland Clinic Foundation, OH 44195, USA
    Mult Scler 11:626-34. 2005
    ..The paucity of data on the long-term treatment of patients with MS may be aided by applying these or similar methods to vigorously followed cohorts of patients...
  8. ncbi Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS
    Richard A Rudick
    Department of Neurology, Center for Multiple Sclerosis Treatment and Research, Cleveland, OH 44195, USA
    Expert Rev Neurother 4:571-80. 2004
    ..Natalizumab may be an important addition to the therapeutic armamentarium for multiple sclerosis...
  9. ncbi Impact of disease-modifying therapies on brain and spinal cord atrophy in multiple sclerosis
    Richard A Rudick
    Department of Neurology, Mellen Center for Multiple Sclerosis Treatment and Research, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    J Neuroimaging 14:54S-64S. 2004
    ..Some of these agents have demonstrated positive effects in well-controlled studies, suggesting that anti-inflammatory therapy can delay or prevent the emergence of irreversible central nervous system pathology...
  10. ncbi Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS
    Richard A Rudick
    Mellen Center for MS Treatment and Research U10, Neurologic Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Neurol Sci 282:106-11. 2009
    ..This study was done to determine the relationship between whole brain, GM, and white matter (WM) atrophy and MS disability progression...
  11. ncbi Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis
    Richard A Rudick
    Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Lancet Neurol 8:545-59. 2009
    ..We also outline possible strategies for the management of patients with breakthrough disease and highlight areas in which research is needed...
  12. ncbi Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a
    R A Rudick
    Mellen Center for Treatment and Research in Multiple Sclerosis, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Neurology 72:1989-93. 2009
    ..Findings from a small clinical study suggested that statins may counteract the therapeutic effects of interferon beta (IFNbeta) in patients with relapsing-remitting multiple sclerosis (RRMS)...
  13. ncbi Assessing disability progression with the Multiple Sclerosis Functional Composite
    R A Rudick
    Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH 44106, USA
    Mult Scler 15:984-97. 2009
    ..However, the clinical meaning of an MSFC Z-score change is not obvious. This study instead used MSFC component data to define a patient-specific disease progression event...
  14. ncbi Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: eight-year follow-up
    Richard A Rudick
    Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195, USA
    Arch Neurol 67:1329-35. 2010
    ..To investigate the value of Expanded Disability Status Scale (EDSS) worsening sustained for at least 6 months and other parameters as predictors for disability status...
  15. ncbi Assessment of JC virus DNA in blood and urine from natalizumab-treated patients
    Richard A Rudick
    Department of Neurology, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Ann Neurol 68:304-10. 2010
    ..Analyses were conducted to determine the clinical utility of measuring JC virus (JCV) DNA in blood or urine of natalizumab-treated multiple sclerosis (MS) patients to predict the risk of progressive multifocal leukoencephalopathy (PML)...
  16. ncbi Gender effects on intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis: analysis of 1406 patients
    R A Rudick
    Mellen Center for Treatment and Research Neurological Institute, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Mult Scler 17:353-60. 2011
    ..We aimed to evaluate effects of gender on efficacy and safety of intramuscular (IM) interferon beta (IFNβ)-1a in patients with relapsing-remitting MS (RRMS) or clinically isolated syndromes (CIS) characteristic of early MS...
  17. ncbi Beta-interferon for multiple sclerosis
    Richard A Rudick
    Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA
    Exp Cell Res 317:1301-11. 2011
    ....
  18. ncbi Excessive biologic response to IFNβ is associated with poor treatment response in patients with multiple sclerosis
    Richard A Rudick
    Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, United States of America
    PLoS ONE 6:e19262. 2011
    ....
  19. ncbi Multiple sclerosis, natalizumab, and PML: helping patients decide
    Richard A Rudick
    Mellen Center for Multiple Sclerosis, Cleveland Clinic, 9500 Euclid Ave, U10, Cleveland, OH 44195, USA
    Cleve Clin J Med 78:S18-23. 2011
    ..Physicians can help patients make individual informed decisions regarding the use of natalizumab, given the known risk of PML...
  20. ncbi Biologic impact of interferon antibodies, and complexities in assessing their clinical significance
    Richard A Rudick
    Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Neurology 61:S31-4. 2003
    ..Therapeutic decisions related to disease management for patients with MS must consider IFNbeta NAb...
  21. ncbi The multiple sclerosis functional composite: a new clinical outcome measure for multiple sderosis trials
    R A Rudick
    Department of Neurology, Mellen Center for Multiple Sclerosis Treatment and Research, The Cleveland Clinic Foundation, Ohio, USA
    Mult Scler 8:359-65. 2002
    ..The studies in aggregate indicate that MSFC and MSFC change are clinically meaningful, and that MSFC has substantial advantages over alternative clinical outcome measures for MS clinical trials...
  22. ncbi Contemporary immunomodulatory therapy for multiple sclerosis
    R A Rudick
    Department of Neurology, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Neuroophthalmol 21:284-91. 2001
    ..There is a tendency toward early diagnosis and treatment based on the hypothesis that treatment effectiveness declines with advancing disease...
  23. ncbi Evolving concepts in the pathogenesis of multiple sclerosis and their therapeutic implications
    R A Rudick
    Mellen Center for Multiple Sclerosis Treatment and Research Department of Neurology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Neuroophthalmol 21:279-83. 2001
    ..These concepts have important implications related to the diagnosis, methods for patient follow-up, type and timing of disease therapy, and the testing of neuroprotective drugs in MS...
  24. ncbi A radical proposal: integrate clinical investigation into the U.S. health care system
    Richard A Rudick
    Department of Neurology, Cleveland Clinic, Cleveland, OH 44195, USA
    Sci Transl Med 1:4cm4. 2009
    ..The integration of a robust clinical research enterprise into the U.S. health care system is now, more than ever, a national priority, and a completely new approach is desperately needed...
  25. ncbi Imaging correlates of decreased axonal Na+/K+ ATPase in chronic multiple sclerosis lesions
    Elizabeth A Young
    Department of Neurosciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA
    Ann Neurol 63:428-35. 2008
    ..To date, however, the distribution of Na+/K+ ATPase has not been studied in MS lesions...
  26. ncbi Activation of the ciliary neurotrophic factor (CNTF) signalling pathway in cortical neurons of multiple sclerosis patients
    Ranjan Dutta
    Department of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Brain 130:2566-76. 2007
    ..Induction of CNTF signalling and the anti-apoptotic molecule, Bcl2, thus represents a compensatory response to disease pathogenesis and a potential therapeutic target in MS patients...
  27. ncbi Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients
    Ranjan Dutta
    Department of Neurosciences, Lerner Research Institute, Cleveland Clinic Foundation, OH 44195, USA
    Ann Neurol 59:478-89. 2006
    ....
  28. ncbi Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group
    R A Rudick
    Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, The Cleveland Clinic Foundation, OH 44106, USA
    J Neuroimmunol 93:8-14. 1999
    ..The objectives of the current study were to determine: (a) whether CSF abnormalities in MS patients correlated with disease or MRI characteristics, and (b) effects of IFNbeta-1a therapy on these CSF abnormalities...
  29. ncbi Multiple sclerosis: chemokine receptor expression on circulating lymphocytes in correlation with radiographic measures of tissue injury
    R J Fox
    Department of Neurology, Mellen Center, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Mult Scler 14:1036-43. 2008
    ..This observation suggests a CKR "set-point" within individuals, which might relate to inflammatory injury in MS. We evaluated the correlation between CKR levels and magnetic resonance imaging (MRI) measures of disease activity...
  30. ncbi Disease-modifying drugs for relapsing-remitting multiple sclerosis and future directions for multiple sclerosis therapeutics
    R A Rudick
    Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic Foundation, Ohio 44106, USA
    Arch Neurol 56:1079-84. 1999
    ..Major issues confronting experimental MS therapeutics are discussed...
  31. ncbi Eight-year follow-up study of brain atrophy in patients with MS
    E Fisher
    Whitaker Biomedical Imaging Laboratory, The Cleveland Clinic Foundation, OH 44195, USA
    Neurology 59:1412-20. 2002
    ..The specific goals of this study were to determine if brain atrophy is related to subsequent disability status and to identify MRI correlates of atrophy progression...
  32. ncbi Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS
    R A Rudick
    Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic Foundation, OH 44195, USA
    Neurology 56:1324-30. 2001
    ..To determine whether the MS Functional Composite (MSFC) can predict future disease progression in patients with relapsing remitting MS (RR-MS)...
  33. ncbi Benefit of interferon beta-1a on MSFC progression in secondary progressive MS
    J A Cohen
    Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic Foundation, OH 44195, USA
    Neurology 59:679-87. 2002
    ..Studies of other IFNbeta preparations in secondary progressive MS (SPMS) yielded conflicting results. This study was undertaken to determine whether IFNbeta-1a slowed disease progression in SP-MS...
  34. ncbi Using an automated recruitment process to generate an unbiased study sample of multiple sclerosis patients
    Deborah M Miller
    Mellen Center for Treatment and Research in Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Telemed J E Health 16:63-8. 2010
    ..The subjects were highly representative of the target population, indicating that there was little bias in our selection process despite a constantly changing pool of eligible individuals...
  35. ncbi Optimal reference population for the multiple sclerosis functional composite
    R J Fox
    Mellen Center for Multiple Sclerosis, Department of Neurology, Cleveland, OH, USA
    Mult Scler 13:909-14. 2007
    ..These results have significant implications to sample size estimates for longitudinal clinical studies and therapeutic trials...
  36. ncbi Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study
    R A Bermel
    Department of Neurology, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH 44195, USA
    Mult Scler 16:588-96. 2010
    ....
  37. ncbi T-cells in the cerebrospinal fluid express a similar repertoire of inflammatory chemokine receptors in the absence or presence of CNS inflammation: implications for CNS trafficking
    P Kivisakk
    Department of Neurosciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Clin Exp Immunol 129:510-8. 2002
    ..Through interactions with its ligands, CXCR3 is proposed to mediate retention of T-cells in the inflamed CNS...
  38. ncbi Natalizumab reduces visual loss in patients with relapsing multiple sclerosis
    L J Balcer
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Neurology 68:1299-304. 2007
    ....
  39. ncbi Mechanisms of disability progression in primary progressive multiple sclerosis: are they different from secondary progressive multiple sclerosis?
    Richard Rudick
    Mellen Center for Multiple Sclerosis, Area U10, Departmentof Neurology, Cleveland Clinic Foundation, Cleveland, OH, USA
    Mult Scler 9:210-2. 2003
  40. ncbi Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis
    Ansi Chang
    Department of Neurosciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    N Engl J Med 346:165-73. 2002
    ..Understanding the cellular interactions between premyelinating oligodendrocytes, axons, and the microenvironment of lesions of multiple sclerosis may lead to effective strategies for enhancing remyelination...
  41. ncbi Longitudinal single-cell cytokine responses reveal recurrent autoimmune myelin reactivity in relapsing--remitting multiple sclerosis patients
    I R Moldovan
    Department of Neurosciences, Cleveland Clinic Foundation, Cleveland, OH 44195 0001, USA
    Mult Scler 11:251-60. 2005
    ..This study also reveals the extremely dynamic nature of the immune reactivity to numerous regions of myelin, which can fluctuate dramatically over time. Such fluctuation could hamper the efficacy of antigen-based therapies for MS...
  42. ncbi Axonal loss in normal-appearing white matter in a patient with acute MS
    C Bjartmar
    Department of Neurosciences, Lerner Research Institute, Cleveland Clinic Foundation, OH 44195, USA
    Neurology 57:1248-52. 2001
    ..Axonal number and appearance was normal in ascending sensory tracts. CONCLUSIONS: These studies confirm axonal degeneration in the absence of myelin loss as one histopathologic correlate to abnormal MR findings in patients with MS...
  43. ncbi Quantification of self-recognition in multiple sclerosis by single-cell analysis of cytokine production
    C M Pelfrey
    Department of Neurosciences, Lerner Research Institute, Department of Neurology, Mellen Center for Multiple Sclerosis Research, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    J Immunol 165:1641-51. 2000
    ..The essential absence of uncommitted Th0 cells producing both cytokines may explain why therapeutic strategies that aim at the induction of immune deviation show little efficacy in the established disease...
  44. ncbi Biomarkers for interferon response in MS: are we there yet?
    Richard A Rudick
    Neurology 70:1069-70. 2008
  45. ncbi Gray matter atrophy in multiple sclerosis: a longitudinal study
    Elizabeth Fisher
    Department of Biomedical Engineering, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Ann Neurol 64:255-65. 2008
    ..To determine gray matter (GM) atrophy rates in multiple sclerosis (MS) patients at all stages of disease, and to identify predictors and clinical correlates of GM atrophy...
  46. ncbi Factors that predict health-related quality of life in patients with relapsing-remitting multiple sclerosis
    Deborah M Miller
    Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Mult Scler 9:1-5. 2003
    ....
  47. ncbi Sex differences in cytokine responses to myelin peptides in multiple sclerosis
    Clara M Pelfrey
    Department of Neurosciences, Cleveland Clinic Foundation, 44195, Cleveland, OH, USA
    J Neuroimmunol 130:211-23. 2002
    ..The data suggest a gender bias towards Th1 responses in MS, which may contribute to the female predominance in this disease...
  48. ncbi Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications
    Robert J Fox
    Department of Neurology Mellen Center, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Mult Scler 11:140-5. 2005
    ....
  49. ncbi Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity
    Robert A Bermel
    Buffalo Neuroimaging Analysis Center, University at Buffalo, State University of New York, USA
    Arch Neurol 62:1371-6. 2005
    ..We hypothesize that interferon beta may exert its effect on brain atrophy in part by reducing a cascade of events that involve iron deposition as a mediator of neurotoxicity or as a disease epiphenomenon...
  50. ncbi Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis
    Robert M Herndon
    University of Mississippi, VA Medical Center, Jackson, MS 39216, USA
    Mult Scler 11:409-19. 2005
    ..Further, the results indicate that persistence of NAbs is dependent on titre and IFNbeta product...
  51. ncbi Effects of sex hormones on costimulatory molecule expression in multiple sclerosis
    Clara M Pelfrey
    Department of Neurosciences, NC30, Lerner Research Institute, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, USA
    J Neuroimmunol 167:190-203. 2005
    ..Thus, although amelioration of MS and other autoimmune diseases during pregnancy is thought to be due to increased sex hormones, the present results do not support a role for suppression of costimulation via estriol or progesterone...
  52. ncbi Association of fatigue and brain atrophy in multiple sclerosis
    Ruth Ann Marrie
    Department of Neurology Mellen Center, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    J Neurol Sci 228:161-6. 2005
    ..This suggests that the subjective complaint of fatigue is linked to destructive pathologic processes in RRMS patients...
  53. ncbi Defining interferon beta response status in multiple sclerosis patients
    Richard A Rudick
    Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, OH 44195, USA
    Ann Neurol 56:548-55. 2004
    ..MRI classification may facilitate rational therapeutic decisions, better clinical trial designs, and studies correlating biomarkers with therapeutic response...
  54. ncbi Interferon gamma responses to myelin peptides in multiple sclerosis correlate with a new clinical measure of disease progression
    Ioana R Moldovan
    Department of Neurosciences, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    J Neuroimmunol 141:132-40. 2003
    ..These data show that myelin-specific T lymphocytes secreting the inflammatory cytokine IFNgamma correlate with functional impairment in MS, supporting an antigen-specific link between the immune response to myelin and disability in MS...
  55. ncbi Flow cytometric analysis of chemokine receptor expression on cerebrospinal fluid leukocytes
    Pia Kivisakk
    Department of Neurosciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Methods 29:319-25. 2003
    ..Here, we describe the methodology used in our laboratory to study chemokine receptor expression on cells in paired samples from peripheral blood and CSF using flow cytometry...
  56. ncbi Drug Insight: interferon treatment in multiple sclerosis
    Ruth Ann Marrie
    Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Nat Clin Pract Neurol 2:34-44. 2006
    ..There is still a need for more effective treatments, which might include new agents or combination therapies...
  57. ncbi Imaging correlates of axonal swelling in chronic multiple sclerosis brains
    Elizabeth Fisher
    Department of Biomedical Engineering, Lerner Research Institute, Cleveland, OH 44195, USA
    Ann Neurol 62:219-28. 2007
    ....
  58. ncbi Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring
    Ludwig Kappos
    University Hospital, Basel, Switzerland
    Lancet Neurol 6:431-41. 2007
    ..Maintaining clinical vigilance allows for early suspension of natalizumab in potential cases of PML, thereby increasing the opportunity for immune reconstitution, which may improve prognosis if PML is confirmed...
  59. ncbi Interferon-beta for multiple sclerosis: Long-term benefits?
    Richard A Rudick
    Ann Neurol 61:283-5. 2007
  60. ncbi Developing a mentorship program for clinical researchers
    Carol E Blixen
    Department of Quantitative Health Sciences, Section on Health Outcomes Research and Clinical Epidemiology, and joint appointment, Department of Bioethics, Cleveland Clinic, Cleveland, Ohio, USA
    J Contin Educ Health Prof 27:86-93. 2007
    ..The U.S. Institute of Medicine and the National Institutes of Health suggest improved mentoring is important to reversing these trends...
  61. ncbi Health-related quality of life in multiple sclerosis: effects of natalizumab
    Richard A Rudick
    Department of Neurology, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Ann Neurol 62:335-46. 2007
    ..To report the relationship between disease activity and health-related quality of life (HRQoL) in relapsing multiple sclerosis, and the impact of natalizumab...
  62. ncbi Atrophy is detectable within a 3-month period in untreated patients with active relapsing remitting multiple sclerosis
    Martin Hardmeier
    MS MRI Evaluation Centre Basel, Basel, Switzerland
    Arch Neurol 60:1736-9. 2003
    ..Brain parenchymal fraction might be a promising measure in future phase 2 studies of agents, with an expected effect on tissue-destructive pathologic mechanisms of MS...
  63. ncbi Interferons in relapsing remitting multiple sclerosis
    Richard A Rudick
    Lancet 361:1824; author reply 1824-5. 2003
  64. ncbi Multiple sclerosis: disease markers accelerate progress
    Robert J Fox
    Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic Foundation, OH, Cleveland, USA
    Lancet Neurol 3:10. 2004
  65. ncbi Primary progressive multiple sclerosis as a phenotype of a PLP1 gene mutation
    Ilka Warshawsky
    Department of Clinical Pathology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Ann Neurol 58:470-3. 2005
    ..This case goes against dogma that mothers of severely affected sons are asymptomatic as adults and expands the differential diagnosis of primary progressive multiple sclerosis to include proteolipid protein 1 gene mutations...
  66. ncbi Interferon-beta 1a does not reduce expression of CCR5 and CXCR3 on circulating T cells
    Pia Kivisakk
    Department of Neurosciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    J Neuroimmunol 141:150-4. 2003
    ....
  67. ncbi Expression of CCR2, CCR5, and CXCR3 by CD4+ T cells is stable during a 2-year longitudinal study but varies widely between individuals
    Pia Kivisakk
    Department of Neurosciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Neurovirol 9:291-9. 2003
    ..The results provide insight into the regulation of CKR expression on CD4+ T cells in vivo, and suggest that major fluctuations of CKR expression in individuals are uncommon...
  68. ncbi Chemokine receptors as biomarkers in multiple sclerosis
    Robert J Fox
    Department of Neurology, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland, OH 44122, USA
    Dis Markers 22:227-33. 2006
    ..Evaluation of chemokines or chemokine receptors as biomarkers in MS will need to account for this individual variability in CKR expression...
  69. ncbi Novel interferon-beta-induced gene expression in peripheral blood cells
    M R Sandhya Rani
    Neuroinflammation Research Center, Department of Neurosciences, Lerner Research Institute, NC30, Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, OH 44195, USA
    J Leukoc Biol 82:1353-60. 2007
    ..Results were validated using RNA obtained ex vivo from blood of patients after injection with IFN-beta. Identification of new ISGs and IRGs in primary PBMC will enhance macroarray assays for monitoring IFN responsiveness...
  70. ncbi Interferon-beta treatment for multiple sclerosis
    Robert A Bermel
    Department of Neurology, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Neurotherapeutics 4:633-46. 2007
    ..The magnitude of the therapeutic effect appears to be similar among products, but the optimal dose, route, and frequency of administration of the drug remain uncertain...

Research Grants9

  1. EXTRAMURAL RESEARCH FACILITIES IMPROVEMENT PROGRAM GCRC
    Richard Rudick; Fiscal Year: 2003
    ..The expected outcome of this construction project will be a centralized facility to conduct innovative, collaborative clinical research protocols and train a new generation of physician scientists. ..
  2. GENERAL CLINICAL RESEARCH CENTER
    Richard Rudick; Fiscal Year: 2006
    ..The GCRC, the centerpiece of our clinical research expansion, is critical to our goal of excellence in clinical research. ..
  3. Case/Cleveland Clinic Clinical Research Training Program (RMI)
    Richard Rudick; Fiscal Year: 2007
    ..It will host a national conference on this theme during 2007 to exchange "lessons learned" and evaluate how NIH-sponsored programs are measuring up to this strategic goal. ..